Endonovo Therapeutics (ENDV) 10-Q 19 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 17, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	1,528,172
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		101,289,580

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash	$ 18,396	$ 988
Other current assets	0	2,000
Total current assets	18,396	2,988
Property Plant and Equipment, net	35,321	42,601
Total Assets	53,717	45,589
Current Liabilities
Accounts payable and accrued expenses	3,757,427	3,167,346
Short term advances	61,255	900
Notes payable, net of discounts of $135,920 as of June 30, 2015 and $2,391 as of December 31, 2014	945,081	1,084,025
Notes payable - related party	341,000	291,000
Derivative liability	157,194	0
Current portion of long term loan	11,852	11,677
Total current liabilities	5,273,809	4,554,948
Long term loan	22,676	28,646
Acquisition payable	155,000	155,000
Total liabilities	5,451,485	4,738,594
Shareholders' deficit
Super AA super voting preferred stock, $0.0001 par value, 1,000,000 authorized and 1,000 issued and outstanding	0	0
Common stock, $.0001 par value; 250,000,000 shares authorized; 96,603,610 and 81,425,957 shares issued and outstanding as of March 31, 2015 and December 31, 2014	9,860	8,143
Additional paid-in capital	1,924,694	1,593,297
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(7,330,752)	(6,292,875)
Total shareholders' deficit	(5,397,768)	(4,693,005)
Total Liabilities and Shareholders' Deficit	$ 53,717	$ 45,589

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Super AA super voting preferred stock
Super AA super voting preferred stock, par value	$ 0.0001	$ 0.0001
Super AA super voting preferred stock, authorized	1,000,000	1,000,000
Super AA super voting preferred stock, issued	1,000	1,000
Super AA super voting preferred stock, outstanding	1,000	1,000
Common Stock
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	98,603,610	81,425,957
Common stock, shares outstanding		81,425,957
Discounts on notes payable	$ 135,920	$ 2,391

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenues, net	$ 1,920	$ 16,422	$ 4,665	$ 34,181
Cost of goods sold	1,338	5,910	2,162	14,358
Gross profit	582	10,512	2,503	19,823
Operating expenses	494,266	836,871	927,820	1,413,306
Loss from operations	(493,684)	(826,359)	(925,317)	(1,393,483)
Other income (expense)
Other income	0	649,800	0	650,335
Amortization of derivative liability discount	(3,521)	0	(3,521)	0
Change in fair value of derivative liability	29,446	0	29,446	0
Interest expense, net	(89,964)	(26,125)	(138,486)	(88,052)
Other income (expense), total	(64,039)	623,675	(112,561)	562,283
Loss before income taxes	(557,723)	(202,684)	(1,037,878)	(831,200)
Provision for income taxes	0	0	0	0
Net loss	$ (557,723)	$ (202,684)	$ (1,037,878)	$ (831,200)
Basic and diluted loss per share	$ (0.01)	$ .26	$ (0.01)	$ (1)
Weighted average common share outstanding:
Basic and diluted	97,996,920	786,497	91,364,222	832,223

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities:
Net loss	$ (1,037,878)	$ (831,200)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	7,280	14,281
Impairment expense	0	12,000
Fair value of equity issued for services	4,251	2,694
Non-cash interest	49,145	0
Amortization of note discount	3,521	6,030
Change in fair value of derivative liability	(29,446)	0
Changes in assets and liabilities:
Other current assets	2,000	(7,000)
Accounts payable and accrued expenses	622,305	317,736
Net cash used in operating activities	(378,822)	(485,459)
Investing activities:
Net cash used in investing activities	0	0
Financing activities:
Proceeds from the issuance of notes payable	290,500	646,897
Proceeds from notes payable - related party	50,000	0
Proceeds from short term advances	73,205	0
Repayments on short term advances	(12,850)	0
Proceeds from issuance of common stock	220	0
Payment against long term loan	(4,845)	0
Payment against notes payable- related party	0	(19,710)
Net cash provided by financing activities	396,230	627,187
Net increase in cash	17,408	141,728
Cash, beginning of year	988	3,255
Cash, end of period	18,396	144,983
Supplemental disclosure of cash flow information:
Cash paid for interest	6,112	0
Cash paid for income taxes	500	0
Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	$ 328,138	$ 0

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - 6 months ended Jun. 30, 2015 - USD ($)	Common Stock	Additional Paid-in Capital	Common Stock Subscription Receivable	Retained Earnings	Total
Beginning balance at Dec. 31, 2014	$ 8,143	$ 1,593,297	$ (1,570)	$ (6,292,875)	$ (4,693,005)
Beginning balance, shares at Dec. 31, 2014	81,425,957
Shares issued for cash	$ 21	199			220
Shares issued for cash, shares	222,775
Share issued for services		3,826			4,251
Shares issued with notes payable	$ 51	454			$ 505
Shares issued with notes payable, shares	505,000				505,000
Share issued for conversion of notes payable and accrued interest	$ 1,220	326,918			$ 328,138
Share issued for conversion of notes payable and accrued interest, shares	12,200,592				12,200,592
Net loss				(1,037,878)	$ (1,037,878)
Ending balance at Jun. 30, 2015	$ 9,860	$ 1,924,694	$ (1,570)	$ (7,330,753)	$ (5,397,768)
Ending balance, shares at Jun. 30, 2015	98,603,610

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Business	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Note 1 - Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) operates in two business segments: 1) intellectual property licensing and commercialization; and 2) biomedical research and development which included the development of the TVEMF device which has been the source of all revenues in the current year. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2015, and 2014 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has raised approximately $401,000 in debt and equity financing for the period January 1, 2015 to June 30, 2015. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from its license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Although, uncertainty exists as to whether the Company will be able to generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. Recent Accounting Standard Updates The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operations. Reclassification The 2014 financial statements have been reclassified to conform to the current year presentation.

Note 2 - Property and Equipment

Note 2 - Property and Equipment	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Note 2 - Property and Equipment	Note 2 - Property and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at June 30, 2015 and December 31, 2014: Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) June 30, December 31, 2015 2014 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 4,945 4,945 74,403 74,403 Less accumulated depreciation 39,082 31,802 $ 35,321 $ 42,601

Note 3 - Notes Payable and Long

Note 3 - Notes Payable and Long Term Loan	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Note 3 - Notes Payable and Long Term Loan	Note 3 - Notes Payable and Long Term Loan Notes Payable In October 2013, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 125,000 shares of its common stock for each unit. In July 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 50,000 shares of its common stock for each unit. In October 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000. The notes bear interest at 10% per annum and are due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 50,000 shares of its common stock for each unit. From January 1, 2014 to June 30, 2015, the company has issued promissory notes for an aggregate principal of approximately $302,500 under this private placement. During the three months ended June 30, 2015, the Company issued and has outstanding one convertible Debenture (“Variable Debenture”) with original terms of 9 months and an interest rate of 8% which contains a variable conversion rate with a discount of 42% of the Company’s common stock based on the average lowest three trading prices 15 days previous to conversion. The Variable Debenture contains a prepayment option which enables the Company to prepay the note for periods of 0-180 days subsequent to issuance at premiums ranging from 120% to145%. The gross amount of the Variable Debenture outstanding is $38,000 as of June 30, 2015. During the three months ended June 30, 2015, a note was reassigned from one investor to another. During this reassignment, the Company entered into negotiations with the new note holder to have the note contain a conversion feature that would allow the note holder to convert the amount of the note into shares of common stock. The note matures in 1 year and has no interest rate. The note contains a variable conversion rate with a discount of 40% of the Company’s common stock based on the Volume Weighted Average Price (“VWAP”) of the 5 preceding days of trading. The convertible note contains a prepayment option which enables the Company to prepay the note at any time. As of June 30, 2015, the outstanding balance of this note was $100,000. As of June 30, 2015 December 31, 2014 Notes payable at beginning of period $ 1,377,416 $ 710,072 Notes payable issued for cash 340,500 935,500 Less amounts converted to stock (295,915) (268,156) Notes payable at end of period 1,422,001 1,377,416 Less debt discount (135,920) (2,391) $ 1,286,081 $ 1,375,025 Notes payable issued to related parties $ 341,000 $ 291,000 Notes payable issued to non-related parties $ 945,081 $ 1,084,025 Derivative Liability The Company issued two Variable Debentures during the three months ended June 30, 2015, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a conversion feature. The Company measures the conversion feature using the Black-Scholes option valuation model using the following assumptions: Six months ended June 30, 2015 2014 Expected term 9 months - 1 year None Exercise price $0.30-$0.52 None Expected volatility 158%-181% None Expected dividends None None Risk-free interest rate 0.28% None Forfeitures None None The time period over which the Company will be required to evaluate the fair value of the conversion feature is nine months or conversion. The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. As of June 30, 2015 and December 31, 2014, the balances of the Derivative Liability are as follows: Derivative Liability Balance December 31, 2014 $ - Issuance of debt 186,640 Change in estimated fair value (1) (29,446) Balance June 30, 2015 $ 157,194 (1) The change in estimated fair value is reflected in interest expense on the statement of operations. Long Term Loan The Company has financed the purchase of an automobile. The future minimum payments on the loan are as follows: Maturity dates of long term debt Twelve months ending, June 30, 2016 $ 11,852 June 30, 2017 $ 12,211 June 30, 2018 $ 10,465 June 30, 2019 $ - $ 34,528 Current portion $ 11,852 Long term portion $ 22,676

Note 4 - Shareholders' Deficit

Note 4 - Shareholders' Deficit	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Note 4 - Shareholders' Deficit	Note 4 - Shareholders’ Deficit Reverse Spilt On April 28, 2014, we concluded the process of changing our corporate name to Endonovo Therapeutics, Inc. and began trading under the symbol ENDV. The Company enacted a reverse stock split effective May 15, 2014. All share and per share numbers in this report have been adjusted for the reverse stock split. Common Stock The Company has entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulate a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant is issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earns over a three-month period. At the anniversary of each quarter, the consultant is issued a new allotment of common stock. In accordance with ASC 505-50 – Equity-Based Payment to non-Employees, the common stock shares issued to the consultant are valued upon their vesting, with interim estimates of value as appropriate during the vesting period. The shares of common stock that have vested through January 2013 were valued based on a valuation performed by an independent valuation firm as the Company had no active market for its shares prior to that time. The Company’s shares began trading in January 2013; as a result the Company utilized market value for its stock when valuing its common stock for the three months ended March 31, 2013. During the second quarter of 2013, the Company revalued the shares based on low trading volume to $0.001. During the six months ended June 30, 2015, the Company granted 4,249,286 shares for services performed by consultants and recorded expense of $4,251. During the six months ended June 30, 2015, the Company issued 505,000 shares of common stock to the purchasers of notes. The share issuance was valued at $505. In addition, during the six months ended June 30, 2015, the Company issued 12,200,592 shares of common stock on the conversion of notes in an amount of $295,915 and accrued interest of $32,223. Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. As of June 30, 2015, there were 1,000 shares of Series AA Preferred stock outstanding.

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Note 5 - Related Party Transactions	Note 5 – Related Party Transactions From time-to-time officers of the Company advance monies to the Company to cover costs. During the six months ended June 30, 2015, officers advanced $18,305 of funds to the Company of which $12,350 was repaid during the period. At June 30, 2015, the balance of short term advances due to related parties was $6,855. During the six months ended June 30, 2015, officers and executives of the Company have entered into note payable agreements amounting to $50,000. The balance of notes payable from related parties at June 30, 2015 is $341,000.

Note 6 - Fair Value Measurement

Note 6 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Note 6 - Fair Value Measurements	Note 6 – Fair Value Measurements Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company's balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Scholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheet at fair value with changes in fair value recorded in the condensed consolidated statement of operation. Endonovo Therapeutics, Inc. and Subsidiaries Notes to Condensed Consolidated Financial Statements (continued) The following table presents the balances of liabilities measured at fair value on a recurring basis by level as of June 30, 2015: Fair Value Measurements Using Quoted Prices in Active Significant Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs As of June 30, 2015 (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 157,194 $ 157,194 Total $ - $ - $ 157,194 $ 157,194 The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the six months ended June 30, 2015: Derivative Liability Balance December 31, 2014 $ - Issuance of debt 186,640 Change in estimated fair value (29,446) Balance June 30, 2015 $ 157,194

Note 1 - Organization and Nat13

Note 1 - Organization and Nature of Business (Policies)	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2015, and 2014 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has raised approximately $401,000 in debt and equity financing for the period January 1, 2015 to June 30, 2015. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management has implemented its business plan to materialize revenues from its license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Although, uncertainty exists as to whether the Company will be able to generate enough cash from operations to fund the Company’s working capital needs or raise sufficient capital to meet the Company’s obligations as they become due, no adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty.
Recent Accounting Standard Updates	Recent Accounting Standard Updates The Company is not aware of any recently issued accounting pronouncements that when adopted will have a material effect on the Company’s financial position or result of its operations.
Reclassification	Reclassification The 2014 financial statements have been reclassified to conform to the current year presentation.

Note 2 - Property and Equipme14

Note 2 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Summary of property and equipment	June 30, December 31, 2015 2014 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 4,945 4,945 74,403 74,403 Less accumulated depreciation 39,082 31,802 $ 35,321 $ 42,601

Note 3 - Notes Payable and Lo15

Note 3 - Notes Payable and Long Term Loan (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of notes payable	As of June 30, 2015 December 31, 2014 Notes payable at beginning of period $ 1,377,416 $ 710,072 Notes payable issued for cash 340,500 935,500 Less amounts converted to stock (295,915) (268,156) Notes payable at end of period 1,422,001 1,377,416 Less debt discount (135,920) (2,391) $ 1,286,081 $ 1,375,025 Notes payable issued to related parties $ 341,000 $ 291,000 Notes payable issued to non-related parties $ 945,081 $ 1,084,025
Variable Debentures Black-Scholes valuation assumptions	Six months ended June 30, 2015 2014 Expected term 9 months - 1 year None Exercise price $0.30-$0.52 None Expected volatility 158%-181% None Expected dividends None None Risk-free interest rate 0.28% None Forfeitures None None
Derivative Liability	Derivative Liability Balance December 31, 2014 $ - Issuance of debt 186,640 Change in estimated fair value (1) (29,446) Balance June 30, 2015 $ 157,194
Schedule of future minimum payments	Maturity dates of long term debt Twelve months ending, June 30, 2016 $ 11,852 June 30, 2017 $ 12,211 June 30, 2018 $ 10,465 June 30, 2019 $ - $ 34,528 Current portion $ 11,852 Long term portion $ 22,676

Note 6 - Fair Value Measureme16

Note 6 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Balances of Liabilities Measured At Fair Value	Fair Value Measurements Using Quoted Prices in Active Significant Other Significant Markets for Observable Unobservable Identical Assets Inputs Inputs As of June 30, 2015 (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 157,194 $ 157,194 Total $ - $ - $ 157,194 $ 157,194
Changes in the Liabilities With Significant Unobservable Inputs	Derivative Liability Balance December 31, 2014 $ - Issuance of debt 186,640 Change in estimated fair value (29,446) Balance June 30, 2015 $ 157,194

Note 1 - Organization and Nat17

Note 1 - Organization and Nature of Business (Details Narrative)	6 Months Ended
	Jun. 30, 2015USD ($)
Organization and Nature of Business (Textual)
Proceeds from the debt and equity financing	$ 401,000

Note 2 - Property and Equipme18

Note 2 - Property and Equipment (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	$ 74,403	$ 74,403
Less accumulated depreciation	39,082	31,802
Property and Equipment, Net	35,321	42,601
Medical Equipment
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	5,000	5,000
Automobiles
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	64,458	64,458
Other Equipment
Property, Plant and Equipment [Line Items]
Property and Equipment Gross	$ 4,945	$ 4,945

Note 3 - Notes Payable and Lo19

Note 3 - Notes Payable and Long Term Loan - Notes Payable (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Notes payable issued for cash	$ 340,500	$ 935,500
Less amounts converted to stock	(295,915)	(268,156)
Less debt discount	(135,920)	(2,391)
Notes payable, Net	1,286,081	1,375,025
Notes payable issued to related parties	341,000	291,000
Notes payable issued to non-related parties	$ 945,081	$ 1,084,025

Note 3 - Notes Payable and Lo20

Note 3 - Notes Payable and Long Term Loan - Derivative Liability (Details) - 6 months ended Jun. 30, 2015 - USD ($)	Total
Debt Disclosure [Abstract]
Expected term, Max	1 year
Expected term, Min	9 months
Exercise price, Max	$ .52
Exercise price, Min	$ .30
Expected volatility, Max	181.00%
Expected volatility, Min	158.00%
Expected dividends	$ 0
Risk-free interest rate	0.28%
Forfeitures	$ 0

Note 3 - Notes Payable and Lo21

Note 3 - Notes Payable and Long Term Loan - Variable Debenture Valuation Assumptions (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Derivative Liability, instant	$ 157,194	$ 0
Issuance of Debt
Derivative Liability, duration	186,640
Change In Estimated Fair Value
Derivative Liability, duration	$ (29,446)

Note 3 - Notes Payable and Lo22

Note 3 - Notes Payable and Long Term Loan - Schedule of Future Minimum Payments (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Long term loan, Maturity dates
June 30, 2016	$ 11,852
June 30, 2017	12,211
June 30, 2018	10,465
June 30, 2019	0
Total	34,528
Current portion	11,852	$ 11,677
Long term portion	$ 22,676	$ 28,646

Note 3 - Notes Payable and Lo23

Note 3 - Notes Payable and Long Term Loan (Details Narrative) - USD ($)	1 Months Ended			2 Months Ended	6 Months Ended
	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Aug. 19, 2015	Jun. 30, 2015
Notes Payable and Long Term Loan
Issuance of notes payable				$ 264,000	$ 186,640
Aggregate principal amount of promissory notes					$ 302,500
Private Placement
Notes Payable and Long Term Loan
Shares issued in private placement, Value	$ 500,000	$ 500,000	$ 500,000
Debt instrument interest rate	10.00%	10.00%	10.00%
Common stock shares issued	50,000	50,000	125,000

Note 4 - Shareholders' Deficit

Note 4 - Shareholders' Deficit (Details) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 31, 2015	Aug. 19, 2015	Jun. 30, 2013	Jun. 30, 2015	Dec. 31, 2014
Equity [Abstract]
Revaluation of shares based on low trading volume			$ 0.001
Share issued for services				$ 4,251
Share issued for service rendered, shares		1,020,000	4,249,286
Shares issued with notes payable				$ 505
Shares issued with notes payable, shares	900,000			505,000
Share issued for conversion of notes payable and accrued interest, shares		100,000		12,200,592
Conversion into common stock				$ (295,915)	$ (268,156)
Accrued interest				$ 32,223

Note 5 - Related Party Transa25

Note 5 - Related Party Transactions (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Related Party Transactions
Related party advances	$ 18,305
Related party advances paid back during period	12,350
Short term advances due to related party	6,855
Notes payable - related party	341,000	$ 291,000
Increase (Decrease) in note payables due	$ 50,000

Note 6 - Fair Value Measureme26

Note 6 - Fair Value Measurements - Balances of Liabilities Measured At Fair Value (Details)	Jun. 30, 2015USD ($)
Quoted Prices In Active Markets For Identical Assets (Level1)
Derivative liability	$ 0
Total	0
SignificantOtherObservableInputs (Level2)
Derivative liability	0
Total	0
SignificantOtherUnobservableInputs (Level3)
Derivative liability	157,194
Total	157,194
Total Derivative Liability
Derivative liability	157,194
Total	$ 157,194

Note 6 - Fair Value Measureme27

Note 6 - Fair Value Measurements - Changes in the Liabilities With Significant Unobservable Inputs (Details) - USD ($)	2 Months Ended	6 Months Ended
	Aug. 19, 2015	Jun. 30, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Liabilities With Significant Unobservable Inputs		$ 157,194	$ 0
Issuance of debt	$ 264,000	186,640
Change in estimated fair value		$ (29,446)

Note 7- Subsequent Events (Deta

Note 7- Subsequent Events (Details) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended	6 Months Ended
	Jul. 31, 2015	Aug. 19, 2015	Jun. 30, 2013	Jun. 30, 2015	Aug. 14, 2015	Dec. 31, 2014
Subsequent Event
Issuance of notes payable		$ 264,000		$ 186,640
Shares issued as a part of notes payable		100,000		12,200,592
Note converted to shares, amount	$ 100,000
Note converted to shares, shares	900,000			505,000
Share issued for services				$ 4,251
Share issued for service rendered, shares		1,020,000	4,249,286
Shares issued in extensino agreement on note payable					250,000
Common stock, shares outstanding		101,289,580				81,425,957